Experienced in Prostate Cancer

Jorg W. Schroder

Aachen, NW, DE 
Experienced in Prostate Cancer
Aachen, NW, DE 
OverviewLocationsClinical Research

Overview

Jorg Schroder practices in Aachen, Germany. Schroder is rated as an Experienced expert by MediFind in the treatment of Prostate Cancer. Their top areas of expertise are Mitral Valve Regurgitation, Urothelial Cancer, Prostate Cancer, Transcatheter Aortic Valve Replacement (TAVR), and Percutaneous Coronary Intervention (PCI).

Their clinical research consists of co-authoring 81 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 9 articles in the study of Prostate Cancer.

Locations

Aachen, NW 52074, Germany
Other Locations
Carl Schurz Str. 31, Berlin, BE 13597, Germany
St. Franziskus Hospital, Siegburg, NW, Germany
Essen, NW 45141, Germany
Koeln, NW, Germany
Potsdam, BB 14467, Germany
Luebeck, SH, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function: The PROTECT IV Trial
Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function: The PROTECT IV Trial
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2025
Intervention Type: Device
Study Phase: Not Applicable
Randomized, Multi-Center, Event-Driven Trial of TAVI Versus SAVR in Patients With Symptomatic Severe Aortic Valve Stenosis and Intermediate Risk of Mortality, as Assessed by STS-Score - DEDICATE
Randomized, Multi-Center, Event-Driven Trial of TAVI Versus SAVR in Patients With Symptomatic Severe Aortic Valve Stenosis and Intermediate Risk of Mortality, as Assessed by STS-Score - DEDICATE
Enrollment Status: Active_not_recruiting
Publish Date: April 26, 2024
Intervention Type: Device, Procedure
Study Phase: Not Applicable
View 1 Less Clinical Trial

81 Total Publications

CO2 Gap Alone Is Not a Prognostic Marker for 28-Day Survival of Patients Undergoing a Transcatheter Aortic Valve Replacement.
CO2 Gap Alone Is Not a Prognostic Marker for 28-Day Survival of Patients Undergoing a Transcatheter Aortic Valve Replacement.
Journal: Journal of clinical medicine
Published: May 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Schroder's expertise for a condition
ConditionClose
      View All 18 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile